AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01225835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Follitrophin alpha
Description: Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
Study NCT01225835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetrorelix
Description: Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
Study NCT02003833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Poly-L-lactic acid
Description: Sculptra injections
Study NCT02003833 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo comparator
Description: saline injections
Study NCT01225835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
Study NCT01627158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol Easyhaler
Description: Budesonide/formoterol Easyhaler
Study NCT01225835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Choriongonadotropin
Description: 10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
Study NCT01225835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choriongonadotropin
Description: 10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
Study NCT01225835 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Progesterone
Description: Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
Study NCT01225835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Progesterone
Description: Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
Study NCT03085550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting
Description: Single treatment fat grafting infiltrated into diabetic ulcer wound
Study NCT01877655 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ASP0113
Description: Intramuscular injection
Study NCT01877655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intramuscular injection
Study NCT01857895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
Study NCT04358458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEN3009
Description: GEN3009 will be administered by intravenous (IV) infusion in cycles of 28 days
Study NCT04358458 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Epcoritamab will be administered by subcutaneous (SC) injections in cycles of 28 days
Study NCT01627158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Symbicort Turbuhaler
Description: Symbicort Turbuhaler
Study NCT01627158 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Charcoal and Budesonide/formoterol Easyhaler
Description: Charcoal and Budesonide/formoterol Easyhaler
Study NCT01627158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Charcoal and Symbicort Turbuhaler
Description: Charcoal and Symbicort Turbuhaler
Study NCT04579770 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: 75g ketone ester in the form of a drink \[96% (R)-3-hydroxybutyl (R)-3-hydroxybutyrate, Oxfordshire, UK)\] will be provided.
Study NCT04579770 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: Sodium bicarbonate - widely accessible food ingredient will be provided.
Study NCT04579770 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03522363 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Streptococcus dentisani CECT7746
Description: Treatment will be applied topically as an adhesive gel with a dental splint
Study NCT04260932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19/CD20 Dual-CAR-T cells
Description: CD19/CD20 Dual-CAR-T cells are prepared via lentiviral infection. 5 days prior to infusion of CAR-T cells, subjects receive fludarabine at dose 30mg/m2/day and cyclophosphamide treatment at dose 250mg/m2 for 3 days and take a rest at least for 2 days before infusion. CD19/CD20 Dual-CAR-T cells will be intravenously infused with a escalated dose of 1-6×106 cells/kg.
Study NCT02581423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m\^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
Study NCT02399917 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV
Study NCT02399917 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lirilumab
Description: Given IV
Study NCT03572777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy
Description: Amoxicillin ('Amoksicilin') 1 g bid 14 days.
Study NCT03572777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy
Description: Clarithromycin ('Makcin') 500 mg bid for 14 days
Study NCT03572777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy
Description: Metronidazole ('Medazol') 500 mg bid for 14 days
Study NCT03572777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant therapy
Description: Esomeprazole ('Emanera') 40 mg bid for 14 days
Study NCT03572777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid therapy
Description: Amoxicillin ('Amoksicilin') 1 g bid 14 days
Study NCT03572777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid therapy
Description: Esomeprazole ('Emanera') 40 mg bid for 14 days
Study NCT03572777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid therapy
Description: Clarithromycin ('Makcin') 500 mg bid for the last 7 days
Study NCT03572777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hybrid therapy
Description: Metronidazole ('Medazol') 500 mg bid for the last 7 days
Study NCT00113386 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: filgrastim
Description: Consolidation chemotherapy
Study NCT00113386 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: pegfilgrastim
Description: Consolidation chemotherapy
Study NCT00113386 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cisplatin
Study NCT00113386 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Study NCT00113386 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: adjuvant therapy
Study NCT00113386 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: conventional surgery
Study NCT00113386 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: neoadjuvant therapy
Study NCT00113386 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study NCT02115347 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Ertugliflozin 15 mg
Description: Tablet
Study NCT02115347 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertugliflozin 15 mg
Description: Tablet
Study NCT03465761 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate
Description: Bilateral side treatment of Essential Tremor
Study NCT03796871 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermapol
Description: Use of the experimental medical device before lesion excision : skin lesion lighting (4 wavelengths) for less than 1 minute and image recording
Study NCT02295163 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: 7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.
Study NCT02295163 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: 7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
Study NCT04403269 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgIV
Description: 2 infusion at D1 and D2 (0.8 g / kg by IV infusion)
Study NCT01555385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast juice
Description: single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
Study NCT01555385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Breakfast juice
Description: single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
Study NCT00722371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
Study NCT01721681 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FACTOR X
Study NCT03327805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Choline
Description: Participants will consume 1000 mg (2x500 mg) of choline bitartrate (over-the-counter supplement) for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of choline bitartrate the evening before the third testing session to study its acute effects.
Study NCT03085550 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat grafting + platelet rich plasma
Description: Single treatment fat grafting mixed with autologous platelet rich plasma infiltrated into diabetic ulcer wound. Autologous PRP is obtained using the ANGEL(TM) Concentrated Platelet Rich Plasma (cPRP) Separation Device which is FDA-regulated and CE certified
Study NCT00255229 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glutamine
Description: Glutamine 10 g four times daily starting two days before treatment for six days in total
Study NCT03327805 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will consume 1000 mg (2x500 mg) of placebo for 28 consecutive days. At baseline, some participants will also be randomly assigned to consume 1000 mg of placebo the evening before the third testing session to study its acute effects.
Study NCT00255229 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Glutamine placebo
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Azithromycin
Description: FMTVDM Planar, SPECT, PET
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Doxycycline
Description: FMTVDM Planar, SPECT, PET
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Clindamycin
Description: FMTVDM Planar, SPECT, PET
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Clindamycin, Primaquine - low dose.
Description: FMTVDM Planar, SPECT, PET
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine, Clindamycin, Primaquine - high dose.
Description: FMTVDM Planar, SPECT, PET
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remdesivir
Description: FMTVDM Planar, SPECT, PET
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: FMTVDM Planar, SPECT, PET
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: FMTVDM Planar, SPECT, PET
Study NCT00836056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin 300 mg capsule
Description: 1 x 300 mg
Study NCT00836056 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cleocin HCl 300 mg capsules
Description: 1 x 300 mg
Study NCT03872596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel IR 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.
Study NCT03872596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seroquel IR 25mg
Description: Administered during Part B, as a single, 25mg dose taken with water.
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-Alpha2B
Description: FMTVDM Planar, SPECT, PET
Study NCT04349410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan
Description: FMTVDM Planar, SPECT, PET
Study NCT03872596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation A 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.
Study NCT03872596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation B 300mg
Description: Administered during Part A, administered orally BID with water, over 5 days.
Study NCT03872596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Formulation 25mg
Description: Administered during Part B, as a single, 25mg dose taken with water.
Study NCT05247723 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV Cannula for aspiration of testicular sperm
Description: After local anesthesia, a wide bore 14-G standard IV cannula was introduced near the lower pole of the testis. The needle was withdrawn and the catheter introduced into the testicular tissue. A 20-ml syringe was secured to the catheter and constant negative pressure applied and secured with a clamp. Back and forth motions were performed covering as many areas of the testis as possible.
Study NCT05247723 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Micro-TESE
Description: Conventional Microscopic Testicular Sperm Extraction (Micro-TESE), Open Testicular Biopsy using surgical Microscope
Study NCT01933360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol sublingual, 1h
Description: Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
Study NCT01933360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo sublingual,1h
Description: Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
Study NCT01933360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol sublingual, 3h
Description: Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy
Study NCT01933360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol vaginal, 1h
Description: Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
Study NCT01933360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol vaginal, 3h
Description: Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
Study NCT01933360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo sublingual, 3h
Description: Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy
Study NCT01933360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo vaginal, 1h
Description: Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
Study NCT01933360 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo vaginal, 3h
Description: Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
Study NCT03157193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyaluronic Acid
Description: Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
Study NCT03157193 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Hydroxypropyl Guar
Description: Hydroxypropyl Guar gel application as sham comparator
Study NCT03222557 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Refer to arm description
Study NCT03222557 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Refer to arm description
Study NCT03222557 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Refer to arm description
Study NCT03222557 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Acupuncture
Description: Refer to arm description
Study NCT00784472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxycodone
Description: intravenous according to patients weight, pn.
Study NCT00784472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: morphine
Description: intravenous administration according to patients weight, pn.
Study NCT06023433 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Elastomeric powerchain
Description: Canine distalization by engaging the elastomeric power chains onto the canine brackets.
Study NCT04645914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Use of nicotine product (smoking/vaping)
Description: The smokers/vapers are consuming during the study one nicotine product of their own. The dose is the same as each individual is consuming regularly
Study NCT01845376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: local anesthesia group
Description: Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.
Study NCT01845376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia group
Description: Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.
Study NCT01845376 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia group
Description: Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
Study NCT03836560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine patch
Description: nicotine patch given for 8 weeks
Study NCT03836560 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine gum
Description: nicotine gum given as requested
Study NCT03753230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroencephalography
Description: Cerebral measurements from electroencephalography devices while music is presented to the participant
Study NCT03753230 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Electroencephalography
Description: Cerebral measurements from electroencephalography devices while music is presented to the participant
Study NCT03466866 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREVENT
Description: Community Health Workers (CHWs), who are race-concordant with participants, will: 1) deliver in-home DM education to increase participants' knowledge and skills; 2) use DM-specific Behavioral Activation to improve DM self-care; and 3) facilitate telehealth visits with the participant's primary care physician (PCP) and a DM nurse educator to increase access to care.
Study NCT03466866 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EUC (Enhanced Usual Care)
Description: In-home diabetes education with no goal setting or telehealth visits
Study NCT00500591 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
Study NCT02259283 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hybrid Knife
Description: POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.